Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Marathon Digital Holdings Inc (MARA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Marathon Digital Holdings Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $295.33 (market cap $8.04B), while Marathon Digital Holdings Inc trades at $12.14 (market cap $4.64B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Marathon Digital Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BIO | MARA | |
|---|---|---|
Market Cap | $8.04B | $4.64B |
Sector | Health | Technology |
52-Week High | $339.75 | $22.84 |
52-Week Low | $241.71 | $6.73 |
Enterprise Value | $7.85B | $6.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
MARA Holdings trades at $12.19, down 3.25% in the last session. The stock faces bearish technical signals and has missed earnings estimates for three consecutive quarters, with a net income margin of -234.83% in 2025. Recent news highlights the company's strategic pivot to AI infrastructure, including a Texas land acquisition adding 2 GW of power capacity, positioning it for potential growth in high-performance computing.
The outlook is mixed: analyst consensus is a Buy with a $17.88 price target, but significant execution risks exist amid persistent losses and high cash burn. Investors must weigh the AI pivot's long-term potential against near-term financial instability and competitive pressures in the evolving digital infrastructure market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →
